It's already known what the expected pricing for CAR-T therapy will be, considering the first of these therapies was approved last year for pediatric leukemia (KYMRIAH/tisagenlecleucel). Expect around $475,000.
Seeing as more is spent on marketing than on drug development, and pharmaceutical marketing is heavily restricted in many other countries, I suspect the only subsidization which is happening is from US consumers to US marketing companies.